MustGrow Biologics Corp. (MGROF)
MustGrow Biologics reports jump in revenue as TerraSante US sales drive growth
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF, FRA:0C0) has reported a sharp increase in revenue for 2025 as it expanded its biological and regenerative agriculture offering. For the year ended December 31, 2025, the company generated sales revenue of $8.3 million, up from $0.4 million in 2024, reflecting increased commercial activity, particularly for its TerraSante biofertility product in the United States.
MustGrow wins Georgia approval for TerraSante biofertility product
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF, FRA:0C0) said Tuesday it has received registration approval from the Georgia Department of Agriculture for its mustard plant-based TerraSante organic biofertility product, expanding the company's commercial footprint in the southeastern US. The Georgia organic certification falls under MustGrow's existing Organic OMRI Listed certifications, which also cover Florida, Arizona, Idaho, Oregon, and Washington State.
MustGrow pivots to US TerraSante growth
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF, FRA:0C0) said on Tuesday it will close its wholly owned Canadian marketing and distribution arm NexusBioAg in April, as the company pivots capital toward its proprietary TerraSante biofertility product in the United States. NexusBioAg, which re-sold and distributed third-party agricultural products to Canadian farmers, operated in a lower-margin and highly price-competitive segment, MustGrow said.
MustGrow Biologics reports positive field trial results for TerraMG in canola production
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF, FRA:0C0) has announced positive results from a two-year field trial program testing its mustard-derived organic biocontrol product, TerraMG, on approximately 100 acres of canola across the Canadian Prairies. The trials, conducted through MustGrow's marketing and distribution subsidiary NexusBioAg, evaluated TerraMG's effectiveness in suppressing clubroot (Plasmodiophora brassicae), a soil-borne parasitic disease that affects canola and for which no registered control products currently exist.
MustGrow Biologics closes $2M financing round
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF, FRA:0C0) announced the closing of its previously announced non-brokered private placement, raising gross proceeds of $2 million. The Saskatoon-based company said it issued 4 million units at a price of $0.50 per unit under the offering, which was completed pursuant to the listed issuer financing exemption.
MustGrow Biologics eyes 2026 growth with TerraSante expansion, TerraMG registrations
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) said it is entering 2026 with optimism, citing accelerating demand for its mustard-derived biofertility product TerraSante in the US, ongoing biopesticide registration efforts for TerraMG, and a rebound anticipated in its Canadian sales and distribution division, NexusBioAg. In a letter to shareholders, CEO Corey Giasson highlighted a “transformational” 2025 as the company transitioned from product development to commercialization.
MustGrow Biologics sees strong potato yield gains – ICYMI
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) earlier this week reported positive field trial results for its biofertility product TerraSante, following large-scale testing in US potato crops. COO Colin Bletsky told Proactive about how farmers have started discussing the product's performance within their local networks.
MustGrow Biologics eyes strong finish to 2025 as it grows revenue, margins during Q3
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF), a provider of regenerative agriculture solutions, reported record third quarter financial results as it expands its presence in Canadian and US markets. Revenue was $0.8 million for the quarter, compared with no revenue in the year-ago period.
MustGrow Biologics reports record second quarter revenue
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF), a provider of innovative regenerative agriculture solutions, has reported record revenue for the second quarter, with sales of $2.8 million for the three months ended June 30, 2025. This compares with no recorded revenue in the same quarter of 2024.
MustGrow Biologics launches $3M private placement
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) said on Wednesday it plans to raise up to C$3 million through a non-brokered private placement, as the agricultural biotech firm looks to ramp up production of its mustard-derived soil bioproducts. The financing will see the company issue up to 4.29 million units at C$0.70 each, with each unit comprising one common share and one five-year warrant exercisable at C$0.90.
MustGrow Biologics enhances exposure to key Canadian phosphate market with RhizoSorb deal
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) has “added another arrow to its NexusBioAg product quiver,” with the signing of a distribution agreement with Phospholutions, analysts at Noble Capital Markets believe. The new agreement broadens NexusBioAg's offerings with the company to sell Phospholutions' RhizoSorb product in Canada.
MustGrow to distribute Phospholutions' RhizoSorb fertilizer efficiency product in Canada
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) said on Tuesday it has entered into a distribution agreement with US-based Phospholutions to bring RhizoSorb phosphorus efficiency technology to the Canadian market. Under the agreement, MustGrow will market and sell RhizoSorb through its sales and distribution division, NexusBioAg.
